


Antibody-Drug Conjugates

Antibody-Drug Conjugates, or ADCs, are purposefully designed to deliver cytotoxins to cancer cells with the potential to treat both solid tumors and hematologic cancers.


MECHANISM OF ACTION

ADCs use a chemical linker to connect cytotoxins with an antibody. The specificity of the antibody enables the ADC to target and bind to cell-surface proteins called antigens that can be found on cancer cells and release its cell-killing drugs only after it has been internalized by the cancer cell. As a result, ADCs have the potential to selectively kill cancer cells.


ADCs use a chemical linker to connect cytotoxins with an antibody



ADC binds to antigens



Cytotoxins are released after being internalized by the cancer cell



ADC selectively kills cancer cell



PFIZER ADC PORTFOLIO

Pfizer is using its understanding of the biology of cancer to explore a number of antibody-linker-cytotoxin combinations and build proprietary ADC platforms using a diverse array of ADC design components.

ONGOING STUDIES

Pfizer is investigating a novel ADC candidate (PF-06647020) targeting PTK7, a receptor tyrosine kinase expressed in many tumor types and associated with poor prognosis.

- A Phase 1 Dose Escalation, Safety and Pharmacokinetic study in adult patients with advanced solid tumors (NCT02222922)¹

For more information, please visit www.pfizerclinicaltrials.com or www.clinicaltrials.gov or call toll-free 1-877-369-9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada).

The safety and efficacy of the agent(s) under investigation have not been established. There is no guarantee that the agent(s) being investigated will receive regulatory approval and become commercially available for use. All information is current as of May 2018.

CONTACT & ADDITIONAL INFORMATION

Pfizer Media Relations Contact

Jessica Smith - Pfizer Oncology Global Media Relations

Phone: 212-733-6213

Mobile: 646-899-3178

Jessica.m.Smith@Pfizer.com

The safety and efficacy of the agent(s) under investigation have not been established. There is no guarantee that the agent(s) being investigated will receive regulatory approval and become commercially available for use. All information is current as of April 2018.

REFERENCE

1. Tolcher AW, Calvo E, Maitland ML, et al. 28LBA A Phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors. *EJC*. doi:10.1016/S0959-8049(16)31946-3.